ESC 365 - The role of adding spironolactone and renal denervation in true resistant hypertension. one-year outcomes of randomized study.

ESC Premium Access

The role of adding spironolactone and renal denervation in true resistant hypertension. one-year outcomes of randomized study.

Session: Resistant hypertension

Topic: Treatment of hypertension

Speaker: Doctor J. Rosa (Nymburk, CZ)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Doctor Jan Rosa

Nymburk Hospital, Nymburk (Czechia)

0 follower

4 more presentations in this session

State of the art in treatment of resistant hypertension.

Speaker: Professor R. Schmieder (Erlangen, DE)

Novel Designer Natriuretic Peptide (ZD100) in Human Resistant-Like Hypertension - A First in Human Study

Speaker: Professor H. Chen (Rochester, US)

SYMPLICITY HTN-3 screen failure patient cohort analysis

Speaker: Doctor R. Waksman (Washington, DC, US)

Future direction for research in management of resistant hypertension.

Speaker: Professor A. Pathak (Monaco, MC)

Access the full session

Resistant hypertension

Speakers: Doctor J. Rosa, Professor R. Schmieder, Professor H. Chen, Doctor R. Waksman, Professor A. Pathak

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources